Clinicoradiological Profile and Treatment Outcomes in Prostate Cancer at a Tertiary Care Cancer Center in India

Abstract

Introduction: Prostate cancer is the most common solid cancer in men and is responsible for 11% of all cancer-related deaths. There are limited data available regarding clinicoradiological (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/computed tomography [CT], magnetic resonance imaging, and bone scan) characteristics, treatment outcomes, and correlation of clinicoradiological characteristics with treatment outcomes of prostate cancer patients from India, especially in the era of PSMA-PET/CT scan. Methodology: This was a single center, retrospective, observational study, conducted for 6 months. We retrospectively collected the data of 332 prostate cancer patients treated between January 2015 and December 2017 at our institute. Results: Three hundred and thirty-two patients were enrolled and were divided into three groups depending on the stage and treatment modality, i.e., Group A, B, and C containing 205, 47, and 80 patients, respectively. The median age was 67 years, and the median prostate-specific antigen (PSA) was 19.3 ng/ml. Lower urinary tract symptoms (83.4%) and bone pain (8.1%) were the common presenting symptoms. PSMA-PET/CT scan revealed regional lymph node metastasis in 56.5% patients, bone metastasis in 35.7%, and visceral metastasis in 11.5% patients, respectively. In patients treated with curative intent, radical prostatectomy was performed in 61.74% of patients, whereas radiation therapy was performed in 47 (14.15%) patients. Among those treated with palliative intent, androgen deprivation therapy (ADT) alone (40) was the most preferred therapy followed by the combination of ADT with docetaxel (28) or abiraterone (12). Significantly (P = 0.006), a greater number of patients who were treated with ADT alone progressed to castration-resistant prostate cancer (CRPC) compared to those on combination ADT with either abiraterone or docetaxel. No significant difference was seen in the disease progression when treatment arm containing ADT with docetaxel was compared to ADT with abiraterone. Conclusion: Patients with metastatic disease had a higher median PSA level and also had a higher likelihood of having Gleason score 8–10. Among patients who were treated with palliative intent for metastatic disease, disease progression to CRPC state was significantly higher in those treated with ADT alone compared to those treated with either ADT + docetaxel or ADT + abiraterone.

Keywords

Abiraterone - docetaxel - prostate cancer - prostate-specific membrane antigen-positron emission tomography/computed tomography

Publikationsverlauf

Eingereicht: 05. April 2019

Angenommen: 19. Januar 2020

Artikel online veröffentlicht:
23. Mai 2021

• References

• 1 Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30: 195-200
• 2 Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M. et al. ⁶⁸Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – Diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging 2018; 45: 235-42
• 3 Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018; 25: 524-31
• 4 Kabasakal L, Demirci E. PSMA PET/CT imaging and therapy. Imaging Med 2015; 7: 49-52
• 5 Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol 2018; 25: 220-31
• 6 Tannock FI, de Wit R, Berry RW, Horti J, Pluzanska A, Chi NK. Docetaxel plus prednisone or mitoxantroneplus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
• 7 Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F. et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016; 70: 256-62
• 8 Kallur KG, Prashanth GR, Krishnappa RS. Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian J Nucl Med 2017; 32: 110-7
• 9 Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D. et al. Transition zone prostate cancers: Features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-92
• 10 Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 1354
• 11 Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O. et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 1028-33
• 12 Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A. et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. J Clin Oncol 2015; 33: 2151-7
• 13 Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-46
• 14 Fizazi K, Tran NP, Fein L, Matsubara N, Antolin RA, Alekseev YB. et al. Abiraterone pluse prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352-60
• 15 James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338-51
• 16 Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T. et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017; 377: 132-42